A study to look at the clinical, human and economic effects on patients who suffer prolonged epileptic seizures

ISRCTN ISRCTN71452613
DOI https://doi.org/10.1186/ISRCTN71452613
Integrated Research Application System (IRAS) 370112
Sponsor UCB
Funder UCB
Submission date
17/09/2026
Registration date
19/11/2026
Last edited
13/11/2026
Recruitment status
Recruiting
Overall study status
Ongoing
Condition category
Nervous System Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
The study is designed to look at patients who suffer from prolonged seizures (PS) in epilepsy. The study will collect information on the clinical effects (medical outcomes), human effects (effects on everyday life) and economic effects (effects on ability to work) in this group of patients.

Who can participate?
Patients aged at least 12 years old who suffer from PS

What does the study involve?
Patients will be asked to complete questionnaires (three times over a 6-month period) and study diaries capturing seizures for 6 months. These will be completed electronically on a phone or tablet.

What are the possible benefits and risks of participating?
There are no benefits from taking part, but the study may collect information which is useful in the treatment of this group of patients in the future.

Where is the study run from?
UCB Biopharma SRL (Belgium)

When is the study starting and how long is it expected to run for?
September 2026 to September 2027

Who is funding the study?
UCB Biopharma SRL (Belgium)

Who is the main contact?
Fiona McNulty, fiona.mcnulty@ubc.com

Contact information

Dr Craig Heath
Principal investigator

Institute of Neurosciences, Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde
Glasgow
G51 4TF
United Kingdom

Phone +44 (0)141 2012374
Email Craig.Heath2@nhs.scot
Ms Fiona McNulty
Public, Scientific

23 Spring Meadows
Warrenpoint
BT34 3SU
United Kingdom

Phone +44 (0)7740651840
Email fiona.mcnulty@ubc.com

Study information

Primary study designObservational
Observational study designProspective observational study
Scientific titleThe clinical, humanistic and economic patient burden of prolonged seizures in epilepsy: a prospective observational study in the UK (RWE1597)
Study acronymRWE1597
Study objectives 1. To characterize the population of patients with PS in terms of demographic and clinical characteristics, including diagnostic and medical history, and seizure type(s)
2. To characterize the patient experience of PS events and clinical outcomes over the observation period
3. To describe healthcare resource utilization (HCRU) in patients with PS
4. To assess health-related quality of life (HRQoL) in patients with PS
Ethics approval(s)

Approved 25/08/2026, Proportionate Review Sub-committee of the South West - Central Bristol Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; -; centralbristol.rec@hra.nhs.uk), ref: 26/SW/0100

Health condition(s) or problem(s) studiedEpilepsy
MethodologyObservational study including questionnaires and patient diaries. Patients will receive usual care. Patients will be asked to complete questionnaires (three times over a 6-month period) and study diaries capturing seizures for 6 months. These will be completed electronically on a phone or tablet.
Intervention typeOther
Primary outcome measure(s)
  1. Health-related quality of life measured using the Patient-Weighted Quality of Life in Epilepsy Inventory (QOLIE-31-P) for adults or Quality of Life in Epilepsy Inventory for Adolescents (QOLIE-AD-48) for adolescents at baseline, 3 months and 6 months
  2. General health status measured using the EuroQol 5-Dimensions, 5-Levels (EQ-5D-5L) or EuroQol 5-Dimensions, 5-Levels Youth version (EQ-5D-Y-5L) at baseline, 3 months and 6 months
  3. Depressive symptoms measured using the Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) or Neurological Disorders Depression Inventory for Epilepsy Youth (NDDI-E-Y) at baseline, 3 months and 6 months
  4. Epilepsy-related stigma measured using the revised Epilepsy Stigma Scale (rESS) or Epilepsy Stigma Scale for Children at baseline and 6 months
  5. Patient-reported experiences and impacts of prolonged seizures measured using non-validated questionnaires at baseline and 3 months
  6. Prolonged seizure characteristics, including seizure frequency, type, duration, associated symptoms, injuries, rescue medication use, recurrence and recovery time, measured using a seizure diary at baseline and monthly from month 1 to month 6
Key secondary outcome measure(s)
Completion date15/09/2027

Eligibility

Participant type(s)
Age groupMixed
Lower age limit12 Years
Upper age limit100 Years
SexAll
Target sample size at registration100
Key inclusion criteria1. Is at least 12 years old at the time of providing assent/consent for study participation
2. Has a documented medical diagnosis of epilepsy
3. Is at risk of prolonged seizures (PS) according to the REST definitions based on physician’s clinical impression of seizure history and disease status
4. Has had at least one PS event within the last month prior to study enrolment evaluation
5. Patient has sufficient cognitive ability to understand the Patient-Reported Outcome questionnaires and seizure diary items and to provide their own answers. Patients may receive non-directive assistance limited to technical or physical support (e.g., typing or navigating the device), provided that all response content is generated by the patient
6. Informed consent and, where applicable, assent for participation will be obtained in accordance with applicable national regulations and the procedures approved by the Ethics Committee
7. The patient, and caregiver/LAR if applicable, has sufficient command of English language to understand the study information and requirements
Key exclusion criteria1. Is enrolled in any clinical trial at the time of assent/consent for study participation
2. Has a history of presence of known non-epileptic seizures which cannot be distinguished from qualifying epileptic seizures
Date of first enrolment09/09/2026
Date of final enrolment09/03/2027

Locations

Countries of recruitment

  • United Kingdom
  • England

Study participating centres

The Royal Wolverhampton NHS Trust
New Cross Hospital
Wolverhampton Road
Heath Town
Wolverhampton
WV10 0QP
England
The Newcastle upon Tyne Hospitals NHS Foundation Trust
Freeman Hospital
Freeman Road
High Heaton
Newcastle upon Tyne
NE7 7DN
England
Sheffield Teaching Hospitals NHS Foundation Trust
Northern General Hospital
Herries Road
Sheffield
S5 7AU
England
University College London Hospitals NHS Foundation Trust
250 Euston Road
London
NW1 2PG
England

Results and Publications

Individual participant data (IPD) Intention to shareNo

Editorial Notes

30/09/2026: Study's existence confirmed by the Proportionate Review Sub-committee of the South West - Central Bristol Research Ethics Committee.